Literature DB >> 16790198

[Permanent His-bundle pacing in patients with infra-Hisian atrioventricular block].

Rafael Barba-Pichardo1, Pablo Moriña-Vázquez, José Venegas-Gamero, Fernando Maroto-Monserrat, Manuela Cid-Cumplido, Manuel Herrera-Carranza.   

Abstract

INTRODUCTION AND
OBJECTIVES: Permanent His-bundle pacing is effective in patients with supra-Hisian atrioventricular block. We report our experience in patients with infra-Hisian atrioventricular block.
METHODS: The study involved selected patients referred for syncope and intraventricular conduction disturbance, infra-Hisian atrioventricular block, with left ventricular dyssynchrony and no coronary sinus access. All patients underwent electrophysiological study to evaluate infra-Hisian atrioventricular conduction, both at baseline and after flecainide administration. We selected patients with an indication for permanent pacing in whom His-bundle pacing produced a narrow QRS complex. Leads were implanted in the right atrium, in the bundle of His, and at the apex of the right ventricle, and connected to the atrial, left ventricular, and right ventricular terminals, respectively, of a biventricular pacemaker generator. All pacemakers were programmed in DDD mode with a left ventricle-right ventricle interval of 80 ms.
RESULTS: Between February and December 2004, seven patients met the study's inclusion criteria. The His-bundle lead was implanted successfully in five. The His-bundle pacing threshold remained stable in two patients, whereas it increased in three. During follow-up, at between 2 and 12 months, no lead dislodgement or failure to capture was observed. Echocardiography did not disclose any deterioration in ventricular function, or any worsening of or new valvular incompetence, but showed that ventricular dyssynchrony had disappeared in previously affected patients.
CONCLUSIONS: His-bundle pacing is the only pacing mode capable of inducing a physiologically normal ventricular contraction. It can be used in some patients with infra-Hisian atrioventricular block.

Entities:  

Mesh:

Year:  2006        PMID: 16790198

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  9 in total

Review 1.  Direct His bundle and paraHisian cardiac pacing.

Authors:  Francesco Zanon; S S Barold
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-04       Impact factor: 1.468

Review 2.  [His-bundle stimulation and alternative RV stimulation sites].

Authors:  G Fröhlig; M Kindermann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-03

Review 3.  [Is resynchronization therapy necessary when optimizing right ventricular stimulation?].

Authors:  G Fröhlig
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-12

4.  Honing in on optimal ventricular pacing sites: an argument for his bundle pacing.

Authors:  Mark Young Lee; Srinath Chilakamarri Yeshwant; Daniel Lawrence Lustgarten
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-04

Review 5.  Permanent His bundle pacing: shaping the future of physiological ventricular pacing.

Authors:  Parikshit S Sharma; Pugazhendhi Vijayaraman; Kenneth A Ellenbogen
Journal:  Nat Rev Cardiol       Date:  2019-06-27       Impact factor: 32.419

Review 6.  His bundle pacing.

Authors:  Jason Payne; Ann C Garlitski; Jonathan Weinstock; Munther Homoud; Christopher Madias; N A Mark Estes
Journal:  J Interv Card Electrophysiol       Date:  2018-08-13       Impact factor: 1.900

Review 7.  His Bundle Pacing: Techniques and Outcomes.

Authors:  Mads Brix Kronborg; Jens Cosedis Nielsen
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

Review 8.  Device Programming for His Bundle Pacing.

Authors:  Haran Burri; Daniel Keene; Zachary Whinnett; Francesco Zanon; Pugazhendhi Vijayaraman
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-02

Review 9.  Innovations in Cardiac Implantable Electronic Devices.

Authors:  Khurrum Khan; Jitae A Kim; Andra Gurgu; Muzamil Khawaja; Dragos Cozma; Mihail G Chelu
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-02       Impact factor: 3.947

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.